SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it was ...

Most patent claims are as broad as possible, and filed down in an iterative process.

A new patent has been published in the US that sounds very similar to one of the Japanese patents which Pocketpair was ...

Enlivex Therapeutics Ltd. (ENLV) is making significant progress in immunotherapy with its innovative Allocetra™ technology.

Japan is the third-largest pharmaceutical market globally and accounts for approximately 5% of the total pharmaceutical sector. The country’s antibiotic resistance market is projected to reach ...

Interestingly, Games Fray also highlights another Nintendo U.S. patent (18/652,883), which was actually filed back in ...

Acurx Pharmaceuticals’ DNA Polymerase IIIC Inhibitors receives Japanese patent: Staten Island, New York Thursday, February 20, 2025, 18:00 Hrs [IST] Acurx Pharmaceuticals, Inc., ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

In September of last year, and in light of a corresponding Japanese patent infringement suit, I published an article ...

To date, Acurx has obtained three U.S. patents, one Israeli patent and now one Japanese patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors ...